Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics

D. Nikoloff, J. C. Shim, M. Fairchild, N. Patten, B. A. Fijal, W. H. Koch, A. MacPherson, D. Flockhart, Y. R. Yoon, J. S. Yoon, Y. H. Kim, J. G. Shin

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

The CYP2D6 gene codes for human cytochrome P450 2D6 enzyme, which is responsible for the metabolism of many psychiatric drugs. In schizophrenic patients treated with neuroleptics, decreased or loss of function CYP2D6 alleles may contribute to the development of tardive dyskinesia (TD), a movement disorder that frequently occurs with chronic neuroleptic treatment. The goal of this study was to determine whether the occurrence of TD is associated with CYP2D6 genotype in a cohort of Korean schizophrenics by employing a CYP450 GeneChip® oligonucleotide microarray and PCR assays to screen for 19 CYP2D6 alleles. Our results revealed that males with at least one decreased or loss of function allele have a moderately greater chance of developing TD than males with only wild-type alleles. Female schizophrenics did not have a significantly greater chance of developing TD. Our results demonstrate the utility of CYP2D6 microarrays to assess genotype status in this Korean cohort.

Original languageEnglish (US)
Pages (from-to)400-407
Number of pages8
JournalPharmacogenomics Journal
Volume2
Issue number6
DOIs
StatePublished - Dec 1 2002

Keywords

  • CYP2D6
  • Genotyping
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Fingerprint Dive into the research topics of 'Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics'. Together they form a unique fingerprint.

  • Cite this

    Nikoloff, D., Shim, J. C., Fairchild, M., Patten, N., Fijal, B. A., Koch, W. H., MacPherson, A., Flockhart, D., Yoon, Y. R., Yoon, J. S., Kim, Y. H., & Shin, J. G. (2002). Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics Journal, 2(6), 400-407. https://doi.org/10.1038/sj.tpj.6500138